NEW DELHI – With three new vaccines in the pipeline over the next two years – for viruses that are common in developing tropical countries – India-based Bharat Biotech International Ltd. (BBIL) continues to pursue its defining mantra of a $1-a-dose vaccine that is within the reach of people in poor countries.